VAb is a biotech spinout from the University of Aberdeen with a focus on the development of antibodies to a wide range of species for research and clinical applications. VAb aims to support the life science community by providing and developing a full range of high quality antibodies.

VAb’s antibodies will be designed for performing in Western Blotting, Immunohistochemistry, Immunofluorescence, ELISA and Flow Cytometry. Monoclonal antibodies will be designed to specifically target key celluar components relevant to cancer, immunological disorders, neurobiology and disease across different species.   

We currently have monoclonal antibodies available to matrix metalloproteinases and Cytochrome P450s among others.